查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
狂犬病免疫球蛋白市場 2022-2028
市場調查報告書
商品編碼
1215774

狂犬病免疫球蛋白市場 2022-2028

Rabies Immunoglobulin Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

在預測期內，全球狂犬病免疫球蛋白市場預計將以 6.1% 的複合年增長率顯著增長。 預計在預測期內，增加 FDA 對主要參與者的批准將對市場產生積極支持。 例如，2021 年 6 月，基於 KEDRAB 在兒科人群中的安全性和有效性的新 FDA 批准在美國上市後臨床試驗中得到證明。 Kedrion Biopharma 和 Kamada Ltd. 是兩家專注於血漿衍生蛋白療法的領先生物製藥公司，已獲得 FDA 批准更新 KEDRAB（狂犬病免疫球蛋白（人））標籤，確認該產品在兒童中的安全性。並宣布它是有效的。

全球狂犬病免疫球蛋白市場根據類型進行細分。 根據類型，市場分為 HRIG 和 ERIG。 ERIG 是一種馬 RIG，由馬生產。 根據世界衛生組織 (WHO) 的說法，廉價且安全（純化、經胃蛋白□消化的馬血清）的馬免疫球蛋白 (ERIG) 數量有限，而且在大多數情況下，最需要它的人無法獲得。看來它是 因此，預測期內的市場增長將受到限制。 已經使用各種免疫原性製劑生產了各種類型的馬抗狂犬病免疫球蛋白 (ERIG)，通常由狂犬病病毒的滅活和固定株組合組成。

從地域上看，全球狂犬病免疫球蛋白市場分為北美、歐洲、亞太地區和世界其他地區。 由於其發達的醫療基礎設施和多家公司的存在，預計北美在預測期內將佔據顯著的市場份額。 該地區的人們對狂犬病有很好的了解，預計將在預測期內推動狂犬病免疫球蛋白市場。 根據疾病預防控制中心的數據，繼兩年零狂犬病病例後，2021 年美國將有 5 人死於狂犬病，這是一年中報告的狂犬病病例數最多的一年。 此外，美國的狂犬病死亡病例很少見，通常每年報告一到三例病例。

內容

第 1 章報告概述

  • 當前行業分析和增長前景
  • 研究方法和工具
  • 市場細分
    • 按細分
    • 按地區

第 2 章市場概述和洞察

  • 調查範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 推薦
    • 總結

第三章競爭格局

  • 主要公司分析
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期趨勢
  • 關鍵策略分析

第四章市場細分

  • 全球狂犬病免疫球蛋白市場：按類型分類
    • 人狂犬病免疫球蛋白 (HRIG)
    • 馬狂犬病免疫球蛋白 (ERIG)

第五章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 世界其他地方

第六章公司簡介

  • Bharat Serums and Vaccines Ltd.（BSV）
  • CSL Behring
  • Grifols SA
  • Guangdong Shuanglin Bio-Pharmacy Co, Ltd.
  • Haffkine Bio-Pharmaceutical Corp. LTD.
  • Kamada Ltd.
  • Lanzhou Institute Of Biological Products Co., Ltd.
  • Premium Serums and Vaccines Pvt.Ltd.（PSVPL）
  • Sanofi SA
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shanghai Serum Bio-technology Co., LTD.
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical CO., Ltd.
  • Sun Pharmaceuticals Co. Ltd.
  • VINS Bioproducts Ltd
Product Code: OMR2026830

Title:Global Rabies Immunoglobulin Market Size, Share & Trends Analysis Report by Type (Human Rabies Immune Globulin (HRIG) and Equine Rabies Immuno Globulin (ERIG)) Forecast Period (2022-2028).

The global rabies immunoglobulin market is anticipated to grow at a substantial CAGR of 6.1% during the forecast period. The increasing FDA approvals to key players are expected to support the market positively during the forecast period. For instance, in June 2021, new FDA Approval based on the safety and effectiveness of KEDRAB in the pediatric population was demonstrated in a US post-marketing clinical trial. Kedrion Biopharma and Kamada Ltd., are two key biopharmaceutical companies focused on plasma-derived protein therapeutics announced the FDA approved a label update for KEDRAB (Rabies Immune Globulin (Human)), establishing the product's safety and effectiveness in children.

The global rabies immunoglobulin market is segmented based on type. Based on the type, the market is segmented into HRIG and ERIG. ERIG is an equine RIG and is produced in horses. According to the World Health Organization (WHO), cheaper and safe (purified pepsin digested horse serum) equine immunoglobulin (ERIG) is available in limited quantities and most situations are inaccessible to those that need it most. Thus, limiting the market growth during the forecast period. Different types of equine antirabies immunoglobulin (ERIG) have been produced using various immunogenic preparations, consisting usually of a combination of inactivated and fixed strains of rabies virus.

Geographically, the global rabies immunoglobulin market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is expected to hold a prominent share in the market during the forecast period due to the well-developed healthcare infrastructure and presence of several players in the region. The people in the region are well aware of rabies disease which is expected to propel the rabies immunoglobulin market during the forecast period. According to the CDC, five people died of rabies in the US in 2021, and following two years of zero rabies cases reported in the US and is the highest number reported per year. Further, rabies deaths in the U.S. are rare, with typically one to three cases reported annually.

The major companies serving the global rabies immunoglobulin market include Bharat Serums and Vaccines Ltd. (BSV), CSL Behring, Grifols SA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2019, Kamada Ltd., a plasma-derived protein therapeutics company entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a US Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product. Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.

Research Methodology

The market study of the global rabies immunoglobulin market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Rabies Immunoglobulin Market Research and Analysis by Type.

The Report Covers:

  • Comprehensive research methodology of the global rabies immunoglobulin market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global rabies immunoglobulin market.
  • Insights about market determinants that are stimulating the global rabies immunoglobulin market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Rabies Immunoglobulin Market by Type
    • 4.1.1. Human Rabies Immune Globulin (HRIG)
    • 4.1.2. Equine Rabies Immunoglobulin (ERIG)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bharat Serums and Vaccines Ltd. (BSV)
  • 6.2. CSL Behring
  • 6.3. Grifols SA
  • 6.4. Guangdong Shuanglin Bio-Pharmacy Co, Ltd.
  • 6.5. Haffkine Bio-Pharmaceutical Corp. LTD.
  • 6.6. Kamada Ltd.
  • 6.7. Lanzhou Institute Of Biological Products Co., Ltd.
  • 6.8. Premium Serums and Vaccines Pvt.Ltd. (PSVPL)
  • 6.9. Sanofi SA
  • 6.10. Shanghai RAAS Blood Products Co., Ltd.
  • 6.11. Shanghai Serum Bio-technology Co., LTD.
  • 6.12. Shenzhen Weiguang Biological Products Co., Ltd.
  • 6.13. Sichuan Yuanda Shuyang Pharmaceutical CO., Ltd.
  • 6.14. Sun Pharmaceuticals Co. Ltd.
  • 6.15. VINS Bioproducts Ltd

LIST OF TABLES

  • 1. GLOBAL RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL HUMAN RABIES IMMUNE GLOBULIN (HRIG) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL EQUINE RABIES IMMUNO GLOBULIN (ERIG) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. NORTH AMERICAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 6. NORTH AMERICAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 7. EUROPEAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 8. EUROPEAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 9. ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 10. ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 11. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RABIES IMMUNOGLOBULIN MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL HRIG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 3. GLOBAL ERIG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL RABIES IMMUNOGLOBULIN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. US RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 6. CANADA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 7. UK RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 8. FRANCE RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 9. GERMANY RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 10. ITALY RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 11. SPAIN RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. REST OF EUROPE RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. INDIA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. CHINA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. JAPAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)